Table 3.

Ongoing clinical trials associated with targeting splicing processes.

No	Ongoing Clinical Trials (accessed date 1 March 2021)
1	Title	A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer
	Conditions	Breast Cancer
	Interventions	Drug: GSK3326595
	URL	https://ClinicalTrials.gov/show/NCT04676516
2	Title	A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS
	Conditions	Neoplasms, Solid Tumor, Adult, Non-Hodgkin Lymphoma, MDS
	Interventions	Drug: JNJ-64619178
	URL	https://ClinicalTrials.gov/show/NCT03573310
3	Title	A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
	Conditions	Advanced Solid Tumors, Metastatic Solid Tumors
	Interventions	Drug: PF-06939999 dose escalationDrug: PF-06939999 monotherapyDrug: PF-06939999 in combination with docetaxel
	URL	https://ClinicalTrials.gov/show/NCT03854227
4	Title	Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin’s Lymphoma (NHL)
	Conditions	Neoplasms
	Interventions	Drug: GSK3326595Drug: Pembrolizumab
	URL	https://ClinicalTrials.gov/show/NCT02783300
5	Title	Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
	Conditions	Neoplasms
	Interventions	Drug: GSK3326595Drug: 5-azacytidineDrug: Best available care
	URL	https://ClinicalTrials.gov/show/NCT03614728
6	Title	A Phase 1 Study to Evaluate H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
	Conditions	MDS, AML, Chronic Myelomonocytic Leukemia (CML)
	Interventions	Drug: H3B-8800
	URL	https://ClinicalTrials.gov/show/NCT02841540